FibroBiologics (NASDAQ:FBLG – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.25, FiscalAI reports.
FibroBiologics Trading Down 2.6%
Shares of FBLG stock opened at $0.90 on Tuesday. The stock has a market cap of $6.02 million, a P/E ratio of -0.17 and a beta of 1.81. FibroBiologics has a 1 year low of $0.62 and a 1 year high of $9.60. The stock has a 50 day simple moving average of $1.16 and a 200 day simple moving average of $2.10.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently weighed in on FBLG shares. HC Wainwright reissued a “buy” rating and set a $6.00 target price (down from $8.00) on shares of FibroBiologics in a report on Tuesday, August 4th. Wall Street Zen upgraded shares of FibroBiologics to a “hold” rating in a research note on Saturday, October 10th. Deutsche Bank lowered shares of FibroBiologics to an “underperform” rating in a research report on Tuesday, August 4th. Finally, Weiss Ratings raised shares of FibroBiologics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday, September 4th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, FibroBiologics has a consensus rating of “Reduce” and an average price target of $73.00.
View Our Latest Research Report on FBLG
FibroBiologics Company Profile
FibroBiologics is a clinical-stage biotechnology company developing cell-based therapies for chronic diseases. Its research centers on fibroblasts, cells found in connective tissue that can support tissue repair and other biological processes. The company is developing potential therapies for conditions including multiple sclerosis, degenerative disc disease, wound healing and diabetes. Its programs are investigational, and the company’s approach includes exploring fibroblast cells and related technologies as treatments.
Read More
- Five stocks we like better than FibroBiologics
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for FibroBiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroBiologics and related companies with MarketBeat.com's FREE daily email newsletter.
